Sage Mountain Advisors LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Sage Mountain Advisors LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 6.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,439 shares of the company’s stock after acquiring an additional 270 shares during the period. Sage Mountain Advisors LLC’s holdings in Eli Lilly and Company were worth $2,588,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the third quarter worth $27,000. Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $35,000. Optiver Holding B.V. purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $36,000. Finally, Family CFO Inc purchased a new position in shares of Eli Lilly and Company in the 3rd quarter valued at $40,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on LLY shares. Bank of America increased their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Barclays raised their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Stock Up 1.2 %

Shares of NYSE LLY traded up $8.45 during trading on Monday, reaching $734.76. 1,361,691 shares of the stock were exchanged, compared to its average volume of 3,050,433. The business’s 50-day moving average price is $763.96 and its 200 day moving average price is $661.44. Eli Lilly and Company has a twelve month low of $370.68 and a twelve month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $698.14 billion, a price-to-earnings ratio of 125.45, a price-to-earnings-growth ratio of 1.58 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period in the previous year, the company posted $2.09 earnings per share. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, equities analysts forecast that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.